Alamar Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	114.05	74.21	25.14
Revenue Growth	-	195.17%	-
Cost of Revenue	46.4	32.51	16.54
Gross Profit	67.66	41.71	8.61
Selling, General & Admin	62.58	35.57	18.94
Research & Development	53.07	37.47	39.23
Operating Expenses	115.65	73.04	58.18
Operating Income	-48	-31.33	-49.57
Interest Expense	-0.82	-0.4	-2.08
Interest & Investment Income	4.92	2.16	4.68
Currency Exchange Gain (Loss)	-0.44	0.42	-0.09
Pretax Income	-54.31	-29.15	-47.06
Income Tax Expense	0.69	0.67	0.01
Net Income	-55	-29.82	-47.07
Preferred Dividends & Other Adjustments	-	-	-0.8
Net Income to Common	-55	-29.82	-46.27
Net Income Growth	-	-	-
Shares Outstanding (Basic)	38	12	11
Shares Outstanding (Diluted)	38	12	12
Shares Change	-	-2.89%	-
EPS (Basic)	-1.44	-2.58	-4.40
EPS (Diluted)	-1.44	-2.59	-4.60
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	-68.47	-58.98	-58.16
Free Cash Flow Per Share	-1.79	-5.11	-4.89
Gross Margin	59.32%	56.20%	34.23%
Operating Margin	-42.08%	-42.22%	-197.15%
Profit Margin	-48.23%	-40.18%	-184.03%
Free Cash Flow Margin	-60.03%	-79.48%	-231.33%
EBITDA	-44.3	-28.57	-47.27
EBITDA Margin	-38.84%	-38.50%	-188.03%
D&A For EBITDA	3.7	2.76	2.29
EBIT	-48	-31.33	-49.57
EBIT Margin	-42.08%	-42.22%	-197.15%
Revenue as Reported	114.05	74.21	25.14
Advertising Expenses	-	1.5	0.9

SEC Filings: 10-K · 10-Q